Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare bill

This article was originally published in The Tan Sheet

Executive Summary

"A prescribed drug or biological product...that is available over-the-counter in addition to being available upon prescription" would be covered by Medicare under legislation introduced April 20 on the Senate and House floors. The clause appears to apply to switch products that still have Rx versions available, such as numerous H2 antagonists. Sen. Edward Kennedy (D-Mass.) introduced the bill (S 841) in the Senate with two cosponsors; the measure was referred to the Finance Committee. Rep. Pete Stark (D-Calif.) introduced the legislation in the House (HR 1495) along with 31 cosponsors; it was referred to the Commerce and Ways & Means Committees

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS089743

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel